Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026
Catalyst overview
Event details
- Drug or asset
- Ersodetug (Monoclonal Antibody)
- Development stage
- Phase 3
- Event type
- Data readout
- Indication
- Tumor-Induced Hyperinsulinism
Research signalsPotential moverHigh management interest
Research summary
What is being tracked?
This catalyst tracks a Phase 3 data readout for Ersodetug (Monoclonal Antibody) in Tumor-Induced Hyperinsulinism. The expected timing is based on the latest available company guidance and may change.
Development notes
03/18/26:- upLIFT Ph3 tumor HI topline data anticipated in H2 2026.
Verification
Primary source
Confirm timing and program details against the company announcement or filing.